Swedish Orphan Financials
| BIOVF Stock | USD 22.87 2.13 8.52% |
Swedish |
Understanding current and past Swedish Orphan Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Swedish Orphan's financial statements are interrelated, with each one affecting the others. For example, an increase in Swedish Orphan's assets may result in an increase in income on the income statement.
The data published in Swedish Orphan's official financial statements usually reflect Swedish Orphan's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Swedish Orphan Biovitrum. For example, before you start analyzing numbers published by Swedish accountants, it's critical to develop an understanding of what Swedish Orphan's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Swedish Orphan's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Swedish Orphan's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Swedish Orphan's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Swedish Orphan Biovitrum. Please utilize our Beneish M Score to check the likelihood of Swedish Orphan's management manipulating its earnings.
Swedish Orphan Stock Summary
Swedish Orphan competes with Collegium Pharmaceutical, Amphastar, Eagle Pharmaceuticals, Alkermes Plc, and Evolus. Swedish Orphan Biovitrum AB , an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. Swedish Orphan Biovitrum AB is headquartered in Solna, Sweden. Swedish Orphan is traded on OTC Exchange in the United States.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | Tomtebodavgen 23A, Solna, |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Benchmark | NYSE Composite |
| Website | www.sobi.com |
| Phone | 46 86 97 20 00 |
| Currency | USD - US Dollar |
You should never invest in Swedish Orphan without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Swedish Pink Sheet, because this is throwing your money away. Analyzing the key information contained in Swedish Orphan's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Swedish Orphan Key Financial Ratios
Generally speaking, Swedish Orphan's financial ratios allow both analysts and investors to convert raw data from Swedish Orphan's financial statements into concise, actionable information that can be used to evaluate the performance of Swedish Orphan over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Swedish Orphan Biovitrum reports annually and quarterly.| Return On Equity | 0.11 | |||
| Return On Asset | 0.0555 | |||
| Beta | 0.39 |
Swedish Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Swedish Orphan's current stock value. Our valuation model uses many indicators to compare Swedish Orphan value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Swedish Orphan competition to find correlations between indicators driving Swedish Orphan's intrinsic value. More Info.Swedish Orphan Biovitrum is number one stock in return on equity category among related companies. It is number one stock in return on asset category among related companies reporting about 0.52 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Swedish Orphan Biovitrum is roughly 1.91 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Swedish Orphan by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Swedish Orphan's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Swedish Orphan's earnings, one of the primary drivers of an investment's value.Swedish Orphan Biovitrum Systematic Risk
Swedish Orphan's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Swedish Orphan volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Swedish Orphan Biovitrum correlated with the market. If Beta is less than 0 Swedish Orphan generally moves in the opposite direction as compared to the market. If Swedish Orphan Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Swedish Orphan Biovitrum is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Swedish Orphan is generally in the same direction as the market. If Beta > 1 Swedish Orphan moves generally in the same direction as, but more than the movement of the benchmark.
About Swedish Orphan Financials
What exactly are Swedish Orphan Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Swedish Orphan's income statement, its balance sheet, and the statement of cash flows. Potential Swedish Orphan investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Swedish Orphan investors may use each financial statement separately, they are all related. The changes in Swedish Orphan's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Swedish Orphan's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.Steps to analyze Swedish Orphan Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Swedish Orphan is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Swedish has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Swedish Orphan's financials are consistent with your investment objective using the following steps:- Review Swedish Orphan's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Swedish Orphan's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Swedish Orphan's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Swedish Orphan's stock is overvalued or undervalued.
Swedish Orphan April 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Swedish Orphan help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Swedish Orphan Biovitrum. We use our internally-developed statistical techniques to arrive at the intrinsic value of Swedish Orphan Biovitrum based on widely used predictive technical indicators. In general, we focus on analyzing Swedish Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Swedish Orphan's daily price indicators and compare them against related drivers.
| Information Ratio | (0.10) | |||
| Maximum Drawdown | 18.84 | |||
| Value At Risk | (6.86) | |||
| Potential Upside | 2.28 |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Swedish Orphan Biovitrum. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Complementary Tools for Swedish Pink Sheet analysis
When running Swedish Orphan's price analysis, check to measure Swedish Orphan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Swedish Orphan is operating at the current time. Most of Swedish Orphan's value examination focuses on studying past and present price action to predict the probability of Swedish Orphan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Swedish Orphan's price. Additionally, you may evaluate how the addition of Swedish Orphan to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |